Immunome Ratios (2023-2025) | IMNM

Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
EBIT Margin -189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
EBITDA Margin -189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
Operating Margin -189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
Net Margin -189.13%-135.42%-121.88%-2,421.17%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
FCF Margin 1,013.11%-138.19%-242.64%-465.45%-1,295.82%-1,088.87%-1,227.01%-1,577.28%-1,938.48%-1,252.95%
Efficiency
Assets Average 44.77M67.30M120.85M234.15M307.98M276.56M248.57M291.47M319.49M297.83M
Equity Average 11.60M7.71M62.98M202.73M269.70M234.37M198.04M244.15M288.20M266.59M
Invested Capital 13.86M9.34M6.08M119.88M285.57M253.84M214.91M181.16M307.13M269.27M263.92M
Asset Utilization Ratio 0.120.050.040.040.040.040.04
Leverage & Solvency
Equity Ratio 0.290.230.070.810.890.860.840.750.900.910.88
Valuation
Enterprise Value 16.53M58.20M11.25M319.07M1,163.53M447.27M637.83M445.56M267.85M541.11M746.66M
Market Capitalization 60.95M96.62M101.89M457.21M1,473.25M725.62M877.99M662.87M585.18M809.21M1,019.30M
Return Ratios
Return on Sales -7.81%-18.71%-25.18%-31.34%-33.82%-19.94%-17.84%
Return on Capital Employed -1.11%-1.17%-1.01%-1.34%-1.57%-0.84%-0.76%-0.88%
Return on Assets -0.91%-1.01%-0.88%-1.15%-1.23%-0.75%-0.70%-0.79%
Return on Equity -1.74%-1.17%-1.01%-1.35%-1.54%-0.89%-0.78%-0.88%